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Abstract
A systematic review and network meta-analysis were conducted to assess the relative efficacy
of antimicrobial therapy for clinical mastitis in lactating dairy cattle. Controlled trials in lac-
tating dairy cattle with natural disease exposure were eligible if they compared an antimicro-
bial treatment to a non-treated control, placebo, or a different antimicrobial, for the treatment
of clinical mastitis, and assessed clinical or bacteriologic cure. Potential for bias was assessed
using a modified Cochrane Risk of Bias 2.0 tool. From 14775 initially identified records, 54
trials were assessed as eligible. Networks were established for bacteriologic cure by bacterial
species group, and clinical cure. Disparate networks among bacteriologic cures precluded
meta-analysis. Network meta-analysis was conducted for trials assessing clinical cure, but
lack of precision of point estimates resulted in wide credibility intervals for all treatments,
with no definitive conclusions regarding relative efficacy. Consideration of network geometry
can inform future research to increase the utility of current and previous work. Replication of
intervention arms and consideration of connection to existing networks would improve the
future ability to determine relative efficacy. Challenges in the evaluation of bias in primary
research stemmed from a lack of reporting. Consideration of reporting guidelines would
also improve the utility of future research.
Introduction
Rationale
Mastitis is one of the most costly diseases of dairy cattle (Halasa et al., 2007). It is painful, can
result in premature culling, reduced milk production, and decreased fecundity at the cow level,
and is often accompanied by herd-level consequences such as poor milk quality and increased
risk of antimicrobial residues in marketed milk. In the United States, treatment for clinical
mastitis represents the most common indication for antimicrobial use in adult dairy cattle,
with 16.4% of cows reported as treated in 2007, with cephalosporins the most commonly
selected drug class (United States Department of Agriculture, 2008). While the bacterial eti-
ology varies, a significant proportion of these cases benefit from prompt administration of
an effective antimicrobial, with or without other therapy. Dairy farmers and veterinarians
have a considerable number of antimicrobial treatments available, including products of
greater importance to human medicine. Veterinarians need information about the relative effi-
cacy among products to facilitate their choices and, where possible, select efficacious products
with the lowest human medical importance.
For many clinical mastitis treatments, comparative efficacy estimates are available for only
one or two antimicrobial products. Ideally, producers and veterinarians would have compara-
tive efficacy of all possible treatment options, to allow the inclusion of relative efficacy with
other treatment decision parameters such as cost, convenience, and importance to human
medicine. Traditionally, information about efficacy would be obtained from randomized con-
trolled trials; however, with so many treatment options for clinical mastitis, a trial that concur-
rently includes all possible treatment options is not feasible. A robust alternative is to conduct
a network meta-analysis that combines all of the information from multiple trials and enables
accurate and valid comparisons to be made for all available treatments. The statistical methods
for this approach are well established and have been used extensively in human health (Dias
et al., 2018) and are beginning to become more common in animal health research (O’Connor
et al., 2013, 2016). Network meta-analysis provides a method of
assessing relative efficacy among many treatments by use of direct
(studies which compare given treatments) and indirect (studies
which share common comparators) evidence, and is a commonly
used approach in human medicine (Caldwell et al., 2005; Cipriani
et al., 2013).
Establishing the relative efficacy of antimicrobial therapies for
clinical mastitis will serve to improve decision makers’ ability to
engage in effective stewardship of antimicrobials by avoiding
unnecessary use of ineffective therapies, and by allowing the selec-
tion of antimicrobials of less importance to human health, if an
equally efficacious antimicrobial is available.
This systematic review was conducted based on the guidance
from the Cochrane Collaboration (Higgins and Green, 2011)
and recommendations for conducting systematic reviews in ani-
mal agriculture and veterinary medicine (O’Connor et al.,
2014a, 2014b; Sargeant and O’Connor, 2014a, 2014b; Sargeant
et al., 2014a, 2014b). It is reported using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) Extension Statement for Reporting of Systematic
Reviews Incorporating Network Meta-analyses of Health Care
Interventions (PRISMA-NMA) (Hutton et al., 2015).
Objectives
The objective of this review was to conduct a systematic review
and network meta-analyses to summarize the results of clinical
trials conducted to evaluate the efficacy of antimicrobials for
the treatment of clinical mastitis in dairy cattle, for both bacterio-
logic and clinical cure.
Methods
Protocol
A review protocol, reported in accordance with PRISMA-P guide-
lines (Moher et al., 2015), was published to the University of
Guelph’s institutional repository (https://atrium.lib.uoguelph.ca/
xmlui/handle/10214/10046) on 2 January 2018. The protocol is
also available through Systematic Reviews for Animals and Food
(SYREAF) (http://www.syreaf.org/contact/).
Eligibility criteria
English-language, primary research studies were eligible for inclu-
sion. Studies must have been conducted in lactating dairy-breed
cattle with naturally occurring clinical mastitis. At least one treat-
ment arm must have included an antimicrobial treatment (given
after diagnosis of clinical mastitis) by any route, compared to no
treatment, placebo, or an alternative treatment (such as another
antimicrobial). Table 1 further describes the treatment groups.
Interventions of long-acting single-dose antimicrobials designed
to be given to cows at dry-off were ineligible. Eligible outcomes
were bacteriologic cure or clinical cure (both as defined by the
authors). Controlled trials with natural disease exposure were
the only eligible study design.
Search
Sources
Electronic searches were completed using CABI (via CAB Direct,
1973 to current), MEDLINE (via Ovid, 1950 to current), Agricola
(via ProQuest, 1970 to current), and Toxline (via ProQuest, 1840
to current) databases. ProQuest Theses and Dissertations (via
ProQuest Central, 1997 to current) were searched. A single
reviewer hand-searched the table of contents of the National
Mastitis Council (NMC) and American Association of Bovine
Practitioners (AABP) conference proceedings from 1997 to
2018, as well as the Bovine Practitioner journal. The Food and
Drug Administration (FDA) website containing the Freedom of
Information New Animal Drug Approvals (NADA) summaries
were also searched by examining all available online summaries.
Search strategy
The search strategy was initially developed for CABI (via Cab
Direct) and consisted of three concepts: dairy cattle (including
breed terms and mastitis terms), antimicrobial treatment, and
outcome terms (clinical or bacteriologic cure). The full search
strategy is listed in Table 2. Database searches were conducted
on 2 February 2018 (CABI) and 12 February 2018 (Medline,
Agricola, Toxline, and ProQuest Theses and Dissertations).
Results from the searches were uploaded to EndNoteX7
(Clarivate Analytics, Philadelphia, PA, USA), and then exported
and uploaded to DistillerSR (Evidence Partners Inc., Ottawa,
ON, USA). Duplicate records were documented and removed
through both EndNoteX7 and DistillerSR. If the same study
appeared as both a conference proceeding and a full publication,
the conference proceeding abstract was removed. Data only avail-
able as a conference proceeding were eligible if the full text was
>500 words, to allow sufficient detail for data extraction and
risk of bias assessment.
Study selection
Distiller SR was used for relevance screening and data extraction.
All screening was conducted independently in duplicate by CBW
and KJC or JMS. The first 250 titles and abstracts were used to
pre-test the questions to ensure clarity and consistency of question
application. Initially, title and abstract were screened for relevance
using the following questions:
(1) Does the title and/or abstract describe a controlled trial? YES
(neutral), NO (exclude), UNCLEAR (neutral);
(2) Does the title and/or abstract describe a study of naturally
occurring clinical mastitis in lactating dairy cows? YES (neu-
tral), NO (exclude), UNCLEAR (neutral);
(3) Does the title and/or abstract describe one or more interven-
tion groups of an antimicrobial therapy, as compared to
either another antimicrobial therapy, a placebo, or no treat-
ment? YES (neutral), NO (exclude), UNCLEAR (neutral);
(4) Is at least one of the mastitis treatments described above NOT
a long-acting, single treatment therapy designed to be given to
cows at dry-off? YES (include for full-text screening), NO
(exclude), UNCLEAR (include for full-text screening)
Citations were excluded if both reviewers agreed the study did not
meet one or more of the descriptions by answering ‘No’ to any of
the previous questions. Disagreements were resolved by consensus
with mediation by JMS or DFK if an agreement could not be
reached. Full-text screening was then conducted by KJC and
CBW independently in duplicate for all studies passing the pri-
mary round, using the first 10 citations as a pre-test. This screen-
ing level used the previous four questions with only ‘YES’
(neutral) or ‘NO’ (exclude) options, and additionally:
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(1) Is the full text available in English? YES (neutral), NO
(exclude);
(2) Is at least one of the mastitis treatments described above given
after the diagnosis of clinical mastitis (i.e. not used for pre-
vention)? YES (neutral), NO (exclude);
(3) Does the study describe an outcome of either bacteriologic or
clinical cure? YES (include for data extraction), NO (exclude)
Citations were excluded if both reviewers agreed the study did not
meet the inclusion criteria by answering ‘No’ to any of the above
questions. Agreement for exclusion at the full-text screening was
at the question level, with conflicts resolved by consensus with
mediation by JMS if an agreement could not be reached.
Data collection
Data from citations meeting the full-text inclusion criteria were
extracted independently in duplicate by CBW and KJC using a
standardized form, which was pre-tested on the first five articles
to ensure clarity and consistency of application. Discrepancies
in data extraction were resolved by consensus, with mediation
by JMS if an agreement could not be reached. A PDF version
of the data extraction tool is available as Supplementary File S1.
Data items
Study characteristics
Study-level data included study location, year of conduct, cattle
breed, farm type (commercial or research), number of farms
enrolled, cow-level inclusion criteria (lactation, number of previous
clinical mastitis events, days since last event, other (specify)), who
determined the diagnosis (producer, veterinarian, or researcher),
how severity was scored, who collected the pre-treatment sample
(producer, veterinarian, or researcher), who was responsible for
treatment (producer, veterinarian, or researcher), and when treat-
ment was administered relative to diagnosis.
Interventions and comparators
Details on the interventions recorded included the type of anti-
microbial drug, route, frequency, duration, concurrent therapy
(including if additional supportive and/or anti-inflammatory
treatment was allowed), and level of treatment allocation. While
results of all comparisons in the network were included in the
analysis, only treatment arms with an intramammary treatment
labeled in North America for use in lactating dairy cattle are pre-
sented with relative efficacy rankings (i.e. other therapies were not
ranked, but information captured on these comparator arms pro-
vided evidence to the network).
Eligible outcomes
Clinical cure and bacteriologic cure(s) (by pathogen or species
group) were extracted for all trials with data presented numeric-
ally. Multiple definitions of a single outcome were extracted




b Intramammary penicillin, naficillin, and aminoglycoside
c Intramammary ceftiofur once daily for two days
d Intramammary ceftiofur, once daily for 3–5 days
e Intramammary ceftiofur, once daily for 8 days
f Non-treated control or placebo
g Parenteral quinolone
h Intramammary quinolone
i Intramammary cloxacillin, parenteral quinolone
j Intramammary cefquinome for 4–5 days
k Intramammary cefquinome for 2 days
l Intramammary and parenteral cefquinome
m Intramammary amoxicillin
n Intramammary and parenteral amoxicillin, clavulanic
acid, and cloxacillin
o Intramammary cefacetrile
p Intramammary rifaximin and cefacetrile
q Intramammary penicillin and aminoglycoside




u Intramammary oleandomycin and aminoglycoside
v Intramammary tetracycline, oleandomycin, and
aminoglycoside
w Intramammary penicillin, neomycin, and
aminoglycoside
x Intramammary cloxacillin
y Intramammary cloxacillin and ampicillin
z Intramammary penicillin
aa Parenteral penicillin
ab Intramammary and parenteral penicillin
ac Parenteral penethamate
ad Intramammary penicillin and cloxacillin
ae Intramammary cephaprin
af Intramammary tetracycline and aminoglycoside
ag Intramammary novobiocin










an Intramammary and parenteral penicillin and neomycin
ao Intramammary pirlimycin and parenteral ceftiofur
ap Intramammary aminopenicillin
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if reported (e.g. bacteriologic cure at 7 days, and at 21 days) but
only one definition (longest cure length) was included in the
meta-analysis.
For trials reporting clinical cure, the duration of time between
treatment and measurement of the outcome was recorded, as well
as the definition of cure and level of analysis (quarter or cow). For
bacteriologic cure, how cure was defined, details on how bacteri-
ology was performed, the species or species groups reported,
when cure was assessed relative to end of treatment, and level
of analysis were recorded. An a priori decision was made with
respect to combining bacteriologic diagnostic information to
group pathogen species that were likely to have a similar response
to treatment. Misclassification of Enterococcus species as
Streptococcus prior to use of MALDI-TOF mass spectrometry
was a concern, and data therefore were not combined for general
Strep. species as this likely would have included misclassified
Enterococcus. Staphylococcus aureus were considered separately
from coagulase-negative Staph species or non-aureus Staph
species, which were grouped. Streptoccus aglactiae, S. uberis,
and S. dysgalactiae were considered unique diagnoses, while
Enterococcus species were considered a unique group.
Escherichia coli and Klebsiella species were considered as separate
diagnoses.
For eligible outcomes, the prioritized outcome metric was
treatment arm-level data (raw data), as this was thought to be
the most prevalent form of data in the literature. Data not pre-
sented as numbers (i.e. data points in graphs) were not extracted.
Geometry of the network
The geometry of the network was visually examined to determine
if some pairwise comparisons dominated and to determine the
network structure, and if there were intervention comparisons
that were not linked to the network (i.e. did not have an interven-
tion in common with one or more other published trials).
Risk of bias in individual trials
The risk of bias was assessed by outcome for each outcome
extracted, using the Cochrane Risk of Bias 2.0 tool (Higgins
et al., 2016), with signaling questions modified to be specific to
the topic of the review (available as Supplementary File S2).
This tool assesses the potential for bias arising from five areas
or domains: bias arising from the randomization process, bias
due to deviations from intended interventions, bias due to
missing outcome data, bias in the measurement of the outcome,
and bias in the selection of the reported results. An additional
potential response was provided for the question on random allo-
cation sequence, for trials using the word ‘random’ to describe the
allocation sequence but not providing details on the method used
to generate the random sequence.
Risk of bias was assessed independently in duplicate, with dis-
agreement resolved by consensus and mediation by JMS or CBW if
needed. Risk of bias is presented by outcome, then by domain of
bias, in order to identify which areas of bias had specific deficiencies.
Summary measures
After extracting the outcomes, the analysis was conducted on the
log OR. For presentation purposes, the log odds ratio was back
transformed to the risk ratio (RR) using the baseline risk from
the model data. The posterior mean and standard deviation of
the baseline risk mean were −0.018 and 0.8697. The posterior
mean and standard deviation of the baseline risk standard devi-
ation were 1.1594 and 0.6285. When trials had zero cells for
some data points, and the odds ratio could not be calculated,
the trial results could not be included in the analyses.
Network meta-analysis
Planned method of statistical analysis
A network meta-analysis was planned for the outcomes of clinical
and bacteriologic cure(s). The method has been previously
described in detail elsewhere (Dias et al., 2010). Briefly
r jk  Bin (p jk, n jk) , u jk = logit (p jk)
and
u jk = {m jb, if k = b; b = A, B, C, . . .m jk + d jk , if k . b; b
= A, B, C . . .
where pjk is the probability of the event in trial j under treatment k
and δjbk is the trial-specific log odds ratio of treatment k relative to
the corresponding baseline treatment b in trial j. The trial-specific
treatment effects are distributed as:
d jbk  N(dbk, s2bk),
Table 2. Full electronic search strategy used to identify studies of the efficacy of antimicrobial therapy for treatment of clinical mastitis in lactating dairy cattle in
CABI (via CAB Direct Web) conducted on 2 February 2018
#1 dairy OR cow OR cattle OR bovine OR holstein OR friesian OR jersey OR ‘brown swiss’ OR aryshire OR guernsey
OR ‘milking shorthorn’ OR ‘norwegian red’
920,047
#2 mastitis OR mastitic 38,812
#3 #1 AND #2 34,340
#4 antibiotic OR antimicrobial OR ‘lactating therapy’ OR treatment OR intramammary OR dicloxacillin OR
cloxacillin OR cephalexin OR ceftiofur OR cephapirin OR pirlimycin OR penicillin OR novobiocin OR amoxicillin
OR ampicillin OR penethamate OR sulfisoxazole OR trimethoprim OR sulfa* OR dihydrostreptomycin OR
erythromycin OR florfenicol OR oxytetracycline OR tetracycline OR tylosin OR liconsamide OR linco*
2,035,401
#5 bacter* OR culture OR cure OR resolution OR resolve 2,064,990
#6 #4 AND #5 572,304
#7 #3 AND #6 10,178
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with priors
dbk  N (0, 10000)
and under the homogeneous variance assumption that σ2bk =
σ2 where σ∼U(0,5)
For multi-arm trials, we assumed the co-variance between δjAB
and δjAC was σ
2/2 (Higgins and Whitehead, 1996; Lu and Ades,
2004).
Selection of prior distributions in Bayesian analysis
The prior distributions were originally based on the approach
reported previously (Dias et al., 2011). For the model, we assessed
σ∼U (0,2) and σ∼U (0,5). As the analysis suggested σ∼U (0,5)
was preferred, we retained this prior in the model.
Implementation and output
All posterior samples were generated using Markov Chain Monte
Carlo (MCMC) simulation implemented using Just Another
Gibbs Sampler (JAGS) software (version 3.4.0) (Plummer,
2015). All statistical analyses were performed using R software
(version 3.2.1) (R Core, 2015) in a Linux system. The model
was fit by calling JAGS from R through the RJAGS package
(Plummer, 2015). Three chains were simulated and the conver-
gence was assessed using Gelman–Rubin diagnostics. A total of
5000 ‘burn-in’ iterations were discarded, and based the inferences
on a further 10,000 iterations. The model output included all pos-
sible pairwise comparisons using log odds ratios (for inconsist-
ency assessment), risk ratios (used for comparative efficacy
reporting), the rankings (for comparative efficacy reporting),
and the probability of being the worst treatment option (for com-
parative efficacy reporting).
Assessment of model fit
The fit of the model was assessed based on the log odds ratio, by
examining the residual deviance between the predicted values
from the mixed-treatment comparison model and the observed
value for each study (Dias et al., 2010).
Assessment of inconsistency
Inconsistency was assessed by examining the estimates of treat-
ment effects obtained from direct, combined, and indirect evi-
dence for all pairwise comparisons, using the method described
by Dias et al. (2010). Means and standard deviations of log
odds ratio of treatment effects were calculated using direct
(head-to-head) evidence only, indirect evidence only, and the
combined evidence. We compared the estimates from the direct
and indirect models and considered the standard deviation of
each estimate, rather than relying on the P-values.
Risk of bias in the overall network
Risk of bias in the overall network of evidence was assessed using
the Confidence In Network Meta-Analysis (CINeMA) platform
(http://cinema.ispm.ch), which uses a frequentist approach
through the ‘metafor’ package (Viechtbauer, 2010) to determine
the basis for the contribution matrix for the risk of bias.
CINeMA evaluates within-study bias, across-studies bias, indir-
ectness, imprecision, heterogeneity, and incoherence. As opposed
to presenting an overall assessment of bias and of indirectness, we
reported the contribution of studies based on the approach to
allocation to groups and blinding, as there is evidence in animal
health that failure to include these design elements is associated
with exaggerated treatment effects (Wellman and O’Connor,
2007; Sargeant et al., 2009a, 2009b). Risk of bias due to random-
ization was assessed as ‘low’ if the authors reported randomization
and details of the method used to generate the sequence; ‘some
concerns’ if random allocation was reported but no details on
how the random sequence was generated were reported; and
‘high’ if no information on allocation was provided or if a non-
random method was used. Risk of bias due to blinding was
assessed as ‘low’ if both caregivers and outcome assessors were
blind to treatment group, ‘unclear’ if caregivers or outcome asses-
sors were blinded, but not both, and ‘high’ if neither caregivers
nor outcome assessors were blinded.
Indirectness (how closely the populations studied resemble the
target populations for the intervention) was not considered to be
an issue due to the eligibility criteria for the review, and therefore
the risk of bias was considered ‘low’ for all studies. Across-study
bias was not assessed as there are no well-developed methods to
determine this in network meta-analysis, and with a small num-
ber of pairwise comparisons, the assessment of small study effect
would not be informative (Sterne et al., 2000). Bias due to impre-
cision was assessed using 0.8 and 1.25 as the clinically important
odds ratios. Similarly, odds ratios of 0.8 and 1.25 were used to
assess heterogeneity. Incoherence (inconsistency) analysis was
not reported from CINeMA, as this was conducted based on
the Bayesian analysis described elsewhere in this paper.
Results
Study selection
The literature search was conducted through the University of
Guelph (Medline, Agricola, and Toxline) and Iowa State
University (CAB Direct). Results of the search and flow of studies
through the screening process are shown in Fig. 1, including rea-
sons for full-text exclusions. The search was validated through the
identification of 10 relevant studies pre-selected by DFK that were
cross-checked for inclusion.
Froman initial search, 14,775 citationswere screened by title and
abstract, 148 of which proceeded to review of full text. Of these, 54
articles were eligible for data extraction, and they contained 54
unique trials. From these 54 trials, 7 did not have usable data (e.g.
data not presented, no variance measure provided for continuous
outcomes, or data were presented in graphs or figures only, and
so 44 trials had data extracted on one or both outcomes. Clinical
cure was reported in 33 trials, and 31 reported bacteriologic cure.
Study characteristics
The 44 trials with data extracted, these were conducted in 20 dif-
ferent countries, most frequently the United States (8/44), Canada
(4/44), New Zealand (4/44), and the United Kingdom (4/44). The
country of conduct was not reported in 10 (23%) trials. Trial set-
ting was most commonly reported as a commercial dairy or dair-
ies (35/44; 80%), with two trials conducted at research dairies and
seven not reporting the trial setting. Twenty-three (52%) trials
reported the year of conduct, with six conducted since 2009
(14%), nine (20%) between 2000 and 2009, six (14%) from
1990 to 1999, and two (5%) prior to 1990. Breed was reported
in 16 (36%) trials, with Holstein/Friesian being most commonly
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reported, although trials in other breeds were also identified. Six
trials were conducted in a single herd (14%), and the number
of herds ranged from 1 to 276. The number of herds used was
not reported in 10 trials (23%).
Further details on the 24 trials included in the network
meta-analysis of clinical cure are presented in Supplementary
File S3, including cow-level eligibility and clinical cure definition.
Outcomes
If outcomes were reported for multiple time points, only the last
measure was included for analysis. Thirty-three trials reported
clinical cure, and 31 reported bacteriologic cure.
Bacteriologic cure
Although 31 trials examined bacteriologic cure, as not all patho-
gens were represented in all trials, a smaller number of trials
reported bacterial cure risks for each species groups. As well,
some trials reported all bacteriologic cures combined together
as a single outcome, which was not considered for further ana-
lysis. Staphylococcus aureus cure was reported by 22 trials with
cure risk reported, 17 trials reported E. coli cure, 15 reported S.
uberis cure, 11 reported coagulase-negative Staphylococcus species
cure, 11 reported S. dysgalactiae cure, seven reported Streptococcus
aglactiae cure, five reported Klebsiella cure, and two reported
Enterococcus cure. Bacteriologic cure was measured at the quarter
level for all trials. Relative to the last day of treatment, the last
assessment of cure ranged from 0 to 30 days.
Clinical cure
Of the 33 trials examining clinical cure, a definition of clinical
cure was provided for the majority (28/33). For the last assess-
ment of cure, time from last treatment ranged from 0 to 100
Fig. 1. Preferred Reporting Items for Systematic
Review and Meta-analysis (PRISMA) study flow
diagram (Moher et al., 2015).
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days. For the 24 trials included in the meta-analysis, 21 provided a
definition of clinical cure, and assessment of cure was last per-
formed at <7 days in five trials, 7–14 days in two trials, 15–21
days in six trials, 22–28 days in seven trials, and 29–35 days in
three trials (days relative to the last treatment administration).
Risk of bias within studies by outcome
Clinical cure
The results of the risk of bias assessment for the 33 trials reporting
clinical cure are presented in Fig. 2, showing the risk of bias in the
five evaluated domains: bias arising from the randomization pro-
cess, bias due to deviations from intended interventions, bias due
to missing outcome data, bias in the measurement of the out-
come, and bias in the selection of the reported results.
For the risk of bias arising from the randomization process, the
majority of trials were assessed as ‘some concerns’ for this domain
(27/33), which was primarily driven by a lack of reporting. Ten
trials used the word ‘random’ to describe allocation, but did not
provide details on how the random sequence was generated,
and 28 did not report information regarding whether the alloca-
tion sequence was concealed prior to enrollment of animals.
The risk of bias due to deviations from intended interventions
was assessed as ‘some concerns’ in the majority of trials (26/33).
This was driven primarily through lack of reporting if caregivers
were or were not blinded. Treatments were commonly co-mingled
in an environmental group, where differential care would be
unlikely, and therefore trials not reporting this feature were
assessed as ‘some concerns’ and not as ‘high risk’.
The risk of bias due to missing outcome data was assessed as
low in 14/33 trials, as a result of either having outcome data
Fig. 2. (a) Risk of bias by domain for trials reporting clinical cure of clinical mastitis following therapy that were included in the final network meta-analysis (n = 24).
Risk of bias was assessed according to the Revised Cochrane risk-of-bias tool for randomized trials (RoB2) (Higgins et al., 2016). (b) Risk of bias by domain for trials
reporting bacteriologic cure of clinical mastitis following therapy (n = 31). Risk of bias was assessed according to the Revised Cochrane risk-of-bias tool for ran-
domized trials (RoB2) (Higgins et al., 2016).
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Fig. 3. (a) Full network plot for the examination of relative efficacy of lactating cow antimicrobial therapy on bacteriologic cure of coagulase-negative
Staphylococcus species. Green circles indicate intramammary treatments of antimicrobials in an OIE category which contains a currently labeled product available
in North America. Red circles indicate a therapy which is a route other than intramammary, or with a product in an OIE category which does not have a currently
labeled intramammary producer in North America. Full treatment arm descriptions are found in Table 1. (b) Full network plot for the examination of relative effi-
cacy of lactating cow antimicrobial therapy on bacteriologic cure of Escherichia coli. Green circles indicate intramammary treatments of antimicrobials in an OIE
category which contains a currently labeled product available in North America. Red circles indicate a therapy which is a route other than intramammary, or with a
product in an OIE category which does not have a currently labeled intramammary product in North America. Full treatment arm descriptions are found in Table 1.
(c) Full network plot for the examination of relative efficacy of lactating cow antimicrobial therapy on bacteriologic cure of Staphylococcus aureus. Green circles
indicate intramammary treatments of antimicrobials in an OIE category which contains a currently labeled product available in North America. Red circles indicate
a therapy which is a route other than intramammary, or with a product in an OIE category which does not have a currently labeled intramammary product in North
America. Full treatment arm descriptions are found in Table 1. (d) Full network plot for the examination of relative efficacy of lactating cow antimicrobial therapy on
bacteriologic cure of Streptococcus dysgalactiae. Green circles indicate intramammary treatments of antimicrobials in an OIE category which contains a currently
labeled product available in North America. Red circles indicate a therapy which is a route other than intramammary, or with a product in an OIE category which
does not have a currently labeled intramammary product in North America. Full treatment arm descriptions are found in Table 1. (e) Full network plot for the
examination of relative efficacy of lactating cow antimicrobial therapy on bacteriologic cure of Streptococcus uberis. Green circles indicate intramammary treat-
ments of antimicrobials in an OIE category which contains a currently labeled product available in North America. Red circles indicate a therapy which is a
route other than intramammary, or with a product in an OIE category which does not have a currently labeled intramammary producer in North America. Full
treatment arm descriptions are found in Table 1.
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available for all, or nearly all, animals which were assigned treat-
ments, or because the proportions of missing data and reasons for
missing data were similar across intervention groups. Similar to
other domains, lack of reporting drove the assessment of ‘some
concerns’ for a majority of trials in this domain, as 13 did not pro-
vide information about the number of animals analyzed (e.g. per-
centage cure was reported as opposed to raw numbers), or no
information was provided for why outcome data were missing.
The risk of bias due to measurement of the outcome was
assessed as ‘high’ for 28/33 trials, and ‘low’ for the remaining
five trials. ‘Low’ risk of bias was assigned if outcome assessors
were blinded to treatment group. As clinical cure is a subjective
measure, a lack of information on blinding or reporting that
blinding was not used, resulted in a ‘high’ risk of bias assessment.
Eight trials reported that blinding was not used, and 20 did not
provide any information on blinding.
For the risk of bias arising from the selection of the reported
results, information regarding a priori intentions of outcome
measurements and analyses were not available for any trials;
this domain generally requires the examination of a trial protocol
or statistical analysis plan documented before the trial if there are
multiple ways an outcome could be measured or analyzed. As a
result, all trials were assessed as ‘some concerns’ in this domain.
Bacteriologic cure
Risk of bias for each domain, and reasons for determination, were
similar for trials reporting bacteriologic cure (n = 31) compared to
those reporting clinical cure. For trials reporting both outcomes,
the risk of bias resulting from the randomization process or devia-
tions from intended interventions were the same. The risk of bias
due to missing outcome data was the same, with a number of
trials failing to report the number of study units analyzed or
why outcome data were missing. The risk of bias due to the meas-
urement of the outcome was assessed as ‘low’ for all trials, as the
assessment of the outcome was unlikely to be influenced by
knowledge of the intervention. As a result, regardless of blinding
status, all trials fell into the ‘low-risk’ category. As there were mul-
tiple ways the outcome could be measured or analyzed, and no
trials gave information regarding an a priori trial protocol or ana-
lysis plan, all were assessed as ‘some concerns’ for this domain.
Quantitative summary
A network meta-analysis was conducted for trials examining clin-
ical cure following antimicrobial therapy for clinical mastitis in lac-
tating dairy cows. Although network meta-analysis was planned for
major bacteriologic categories, none of the networks were consid-
ered large and diverse enough to conduct a meaningful network
meta-analysis. For coagulase-negative Staphylococcus species (Fig.
3a), E. coli (Fig. 3b), S. aureus (Fig. 3c), S. dysgalactiae (Fig. 3d),
and S. uberis (Fig. 3e), the networks of evidence were very discon-
nected, i.e. common treatment arms did not exist between many of
the studied treatments. As a result, it was not possible to provide
relative comparisons of treatments which did not share a common
Fig. 4. Full network plot for the examination of
relative efficacy of lactating cow therapy for clin-
ical mastitis on clinical cure rate. The largest net-
work in this full plot used for network
meta-analysis is further shown in Fig. 5. Full
treatment arm descriptions are found in Table 1.
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Table 3. Direct (dir) and indirect (rest) comparisons for the consistency assumption
Comparison d(dir) SD(dir) d(MTC) SD(MTC) d(rest) SD(rest) ωXY SD ωXY P
b versus x −0.2422794 0.72213542 −0.2234246 1.0832922 −0.2573588 NA 0.01507939 NA NA
c versus e −0.0041199 1.45911667 0.03013332 0.32003286 0.03186441 0.32802015 −0.0359843 1.49553291 0.98080381
d versus h 2.41112921 2.94287634 2.55535025 0.66838289 2.56319422 0.68631843 −0.152065 3.02184615 0.95986588
d versus ae −0.0069517 2.89699504 −0.1038346 0.54346414 −0.1073685 0.55328702 0.10041685 2.94935702 0.97283965
d versus af 0.18086809 2.92383482 −0.207945 0.62255709 −0.2264098 0.63716827 0.40727784 2.99245609 0.89174102
d versus ao −0.4835095 2.8681265 0.47043786 0.58480292 0.51181765 0.5973519 −0.9953271 2.92967215 0.73405226
a versus z 0.40566788 2.88633668 0.41840249 1.01868981 0.42021446 1.08875353 −0.0145466 3.08485392 0.9962376
g versus d −0.4623023 2.90728499 0.26331685 0.56619357 0.29192275 0.57724614 −0.7542251 2.96403764 0.79914123
h versus g 2.84941886 2.92867922 −2.8186671 0.67238208 −3.1340527 0.69083532 5.98347156 3.00905556 0.04675772
h versus q −1.5306918 2.93740582 −1.4449063 0.8929376 −1.4361717 0.9372944 −0.09452 3.08332187 0.97554447
o versus b −0.1260423 0.63711759 0.13097622 1.09343582 −0.2581569 NA 0.13211458 NA NA
q versus a 0.26490511 2.88532773 −0.2865591 1.0093283 −0.3634509 1.07739932 0.62835605 3.07991971 0.8383402
q versus r 0.04191554 2.88379282 0.05554777 1.00594688 0.05743636 1.07336853 −0.0155208 3.07707346 0.99597547
q versus ah −0.1848829 2.94009574 0.22263304 1.02986869 0.27962803 1.09953112 −0.4645109 3.13896984 0.88235701
f versus c 0.86836298 0.54399536 0.86098992 0.17175413 0.86017357 0.18101293 0.00818942 0.57332071 0.98860326
f versus g 0.99815797 3.0225277 0.06115846 0.57291071 0.02623935 0.58348837 0.97191862 3.07833273 0.75220828
f versus m −0.2307719 1.56964594 0.0599287 0.44045566 0.0847752 0.45889289 −0.3155471 1.63535044 0.84699515
x versus a −0.1446274 2.88740676 0.17255359 1.05598303 0.22152724 1.13458134 −0.3661546 3.10232052 0.90604702
x versus o −0.1182636 0.68639613 0.09244842 1.09368143 −0.2551944 NA 0.13693085 NA NA
y versus ah −0.6857513 2.93109053 0.68157887 1.09694094 0.9042748 1.18290174 −1.5900261 3.16078285 0.61493039
z versus q 0.15817798 2.88462984 −0.1318434 1.00156433 −0.171599 1.0680067 0.32977695 3.07599214 0.91462242
z versus ap −1.1419929 3.07533328 1.0632024 1.30170297 1.5445154 1.43675415 −2.6865083 3.39439793 0.42867937
aa versus z −0.4862815 1.45015308 −0.4834464 1.0311489 −0.4805469 1.46651412 −0.0057347 2.0624276 0.99778146
ac versus y 0.21328214 2.94031646 0.20502078 1.20856504 0.2033413 1.32573222 0.00994084 3.22537235 0.99754086
ae versus m 0.02595815 2.91873711 −0.160712 0.48899426 −0.1661028 0.49600484 0.19206096 2.96058223 0.94827536
ag versus q −2.4844861 3.19513693 −2.4076424 1.40731505 −2.3891464 1.56755956 −0.0953397 3.55895251 0.97862827
The inconsistency estimate (ωXY) and standard deviation (SDωXY) are shown. Posterior means (d) and standard deviation (SD) of the log odds ratio of intervention effects calculated for direct (head-to-head) evidence only (dir), indirect evidence only









comparator, nor was additional strength provided by the use of
indirect estimates, as compared to the larger, more connected net-
work of trials for the clinical cure outcome (Fig. 4). For S. aglactiae,
Klebsiella, and Enterococcus, too few trials were found to inform the
composition of a treatment network.
Network meta-analysis – clinical cure
The full network plot for clinical cure is shown in Fig. 4. Fifteen
treatment arms were not connected to the larger network (and,
were each only connected to one or two other arms), and so
could not be included in the meta-analysis. The network of evi-
dence used in meta-analysis is shown in Fig. 5, and represents
51 treatment arms from 24 trials, including 21 two-arm trials
and three three-arm trials.
Assessment of consistency
The consistency assessment relates only to outcome (clinical cure)
for which a network meta-analysis was conducted, and is shown
in Table 3. The means and standard deviations of log odds ratio
of treatment effects are shown using direct (head-to-head) evidence
only, indirect evidence only, and the combined evidence. The incon-
sistency estimate and standard deviation are presented. The approach
used to assess inconsistency was to evaluate the direction of the esti-
mates and determine if they were indicative of different effects com-
bined with an evaluation of the width of the credible intervals. Using
this approach, there was one of 25 comparisons which had a concern
regarding the inconsistency estimate: treatment h (intramammary
quinolone) compared to treatment g (parenteral quinolone).
The contribution of trials to estimates based on the randomiza-
tion status of the study is presented in Fig. 6, and contribution of
studies to estimates based on blinding is presented in Fig. 7. Most
pairwise comparisons included a roughly equal contribution from
trials which randomly allocated to treatment and provided evidence
of random sequence generation (green), and those which did not
report random allocation or reported a non-random method
(red) (Fig. 6). A smaller contribution came from trials which
described random allocation with no supporting evidence (yellow).
For contribution of trials to estimates based on blinding (Fig. 7), in
most pairwise comparisons, there was only a very small (or no) con-
tribution from studies reporting blinding of both (green) or either
(yellow) caregivers or outcome assessors. Table 4 further sum-
marizes the risk of bias conclusion for each pairwise comparison
for randomization, blinding, imprecision, and heterogeneity.
Rankings and distribution probability of clinical cure
The rankings and probability distributions are only shown for intra-
mammary antimicrobials belonging to a category where there is a
currently labeled product in North America. Risk ratios from the
network meta-analysis comparing these treatments are shown in
Table 5. The risk ratio is the risk of the event (clinical cure) in
the column heading (the treatment arm included as the numerator
in the risk ratio), divided by the risk of the event in the row header
(the treatment arm included as the denominator in the risk ratio).
For example, the estimated probability of clinical cure for f (non-
treated control) is 0.69 times the probability of cure for cows treated
with intramammary penicillin (treatment z). The corresponding
confidence interval is located in the lower left-hand section of the
Fig. 5. Treatment arm network for the examin-
ation of relative efficacy of lactating cow anti-
microbial therapy for clinical mastitis on clinical
cure rate. The size of the circle indicates the rela-
tive number of arms and the width of the lines
indicates the relative number of direct compari-
sons. Full treatment arm descriptions are found
in Table 1. Treatment arms c, d, e, m, q, s, x, z,
ae, and ap are intramammary therapies from cat-
egories with current labeling for lactating cow
therapy in North America, treatment arm f is non-
treated control or placebo group.
Animal Health Research Reviews 239
table, with rows and columns reversed to those used for the risk
ratio (95% CI 0.30–1.59). Although almost all products were
numerically better than non-treated controls, all credibility intervals
overlapped a value of one, as do pairwise comparisons between
products, meaning results are consistent with no effect. The distri-
bution of the probability of clinical cure is shown in Figure 8. Mean
rankings and 95% credibility intervals are shown as a forest plot
(Fig. 9), and as a table in Supplementary File S4.
Fig. 6. Contribution of studies to the point estimates based on the description of allocation approach for studies contributing to the network meta-analysis exam-
ining the relative efficacy of intramammary lactating cow therapy on the risk of clinical cure (n = 24). Green indicates studies that randomly allocated to treatment
and provided evidence of random sequence generation, yellow indicates studies that reported random allocation but did not provide supporting evidence, and red
indicates studies that did not report allocation approach or reported a non-random method. White vertical lines indicate the percentage contribution of separate
studies.
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Discussion
Summary of evidence
As treatment of clinical mastitis reflects a large proportion of anti-
microbial use in the dairy cattle industry, optimizing the use in
this area can have a significant impact on overall Antimicrobial
use (AMU). Evidence around efficacy can allow for the selection
of an equally efficacious product of lesser importance to human
health, and avoiding selection of ineffective antimicrobials can
reduce unnecessary use where there is no benefit to animal health
Fig. 7. Contribution of studies to the point estimates based on the description of blinding for studies contributing to the network meta-analysis examining the
relative efficacy of intramammary lactating cow therapy on the risk of clinical cure (n = 24). Green indicates studies that reported both caregivers and outcome
assessors were blinded to treatments, yellow indicates studies that reported caregivers or outcome assessors were blinded to treatment (but not both), and
red indicates studies where blinding was not used, or not reported, for both caregivers and outcome assessors. White vertical lines indicate the percentage con-
tribution of separate studies.
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Table 4. Summary of the overall quality of evidence of the network of studies examining the efficacy of intramammary lactating therapy on clinical cure, using the Confidence In
Network Meta-Analysis (CINeMA) platform (http://cinema.ispm.ch), with a modified approach, to determine the risk of bias due to approach to randomization, blinding,
imprecision, and heterogeneity
Comparison Number of studies Randomization Blinding Imprecision Heterogeneity
ae:d 1 No concerns Major concerns No concerns Some concerns
ae:m 1 No concerns Major concerns Some concerns Some concerns
ao:d 1 No concerns Major concerns Some concerns No concerns
ao:z 1 Some concerns Major concerns Some concerns No concerns
c:e 1 No concerns Major concerns No concerns No concerns
c:f 3 Major concerns Major concerns Some concerns No concerns
f:m 1 Major concerns Major concerns Major concerns No concerns
q:z 1 Major concerns Major concerns No concerns No concerns
ae:ao 0 No concerns Major concerns Some concerns No concerns
ae:c 0 No concerns Major concerns Some concerns No concerns
ae:e 0 No concerns Major concerns Some concerns No concerns
ae:f 0 No concerns Major concerns Major concerns No concerns
ae:q 0 No concerns Major concerns Some concerns Some concerns
ae:x 0 Major concerns Major concerns Some concerns Some concerns
ae:z 0 No concerns Major concerns Some concerns Some concerns
ao:c 0 No concerns Major concerns Major concerns No concerns
ao:e 0 No concerns Major concerns Major concerns No concerns
ao:f 0 No concerns Major concerns Some concerns Some concerns
ao:m 0 No concerns Major concerns Some concerns No concerns
ao:q 0 No concerns Major concerns Some concerns No concerns
ao:x 0 Major concerns Major concerns Some concerns No concerns
c:d 0 Major concerns Major concerns Some concerns No concerns
c:m 0 Major concerns Major concerns Some concerns No concerns
c:q 0 Major concerns Major concerns Some concerns No concerns
c:x 0 Major concerns Major concerns No concerns Some concerns
c:z 0 Major concerns Major concerns Some concerns No concerns
d:e 0 No concerns Major concerns Some concerns No concerns
d:f 0 No concerns Major concerns Major concerns No concerns
d:m 0 No concerns Major concerns Major concerns No concerns
d:q 0 No concerns Major concerns Some concerns Some concerns
d:x 0 Major concerns Major concerns Some concerns Some concerns
d:z 0 No concerns Major concerns Some concerns Some concerns
e:f 0 No concerns Major concerns Some concerns No concerns
e:m 0 No concerns Major concerns Some concerns No concerns
e:q 0 No concerns Major concerns Some concerns No concerns
e:x 0 Major concerns Major concerns No concerns Some concerns
e:z 0 No concerns Major concerns Some concerns No concerns
f:q 0 No concerns Major concerns Some concerns Some concerns
f:x 0 Major concerns Major concerns Some concerns Some concerns
f:z 0 Major concerns Major concerns Some concerns Some concerns
m:q 0 No concerns Major concerns Some concerns Some concerns
m:x 0 No concerns Major concerns Some concerns Some concerns
m:z 0 No concerns Major concerns Some concerns Some concerns
q:x 0 Major concerns Major concerns No concerns No concerns
x:z 0 Major concerns Major concerns No concerns Some concerns
Imprecision and heterogeneity were determined using a clinically important odds ratio of 0.8.
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or welfare. Based on the information in the network, although
most antimicrobial treatments were numerically superior to non-
treated controls, large credibility intervals meant that no treat-
ments were statistically different than each other or non-treated
controls. As a result, we cannot conclude whether our results
for this outcome were due to treatments being equivalent, or
were due to a lack of power within the network. This could be fur-
ther confounded by pathogen causing the clinical mastitis, given
the small number of trials. This review provides information on
the geometry of the networks, and identifies current gaps which
can be addressed in future work in order to build the value of
both future work and the entire body of evidence.
Limitations of the body of evidence
Although a large number of trials evaluated the outcomes of bac-
teriologic and clinical cure, and included the major species groups
per-defined, the lack of replication of interventions lead to dispar-
ate networks in the case of bacteriologic cure, and contributed to
the lack of precision in the clinical cure network. In order to util-
ize the information from all trials, each trial must connect to at
least one other trial through at least one common intervention
arm. Future research could consider the geometry of these net-
works, and if disconnected intervention arms are of importance,
trials with one arm connecting to a larger body of evidence
would serve to increase the value of the work conducted beyond
the comparisons in a single trial. Replication of interventions
would also increase the precision of point estimates which
would allow for a better assessment of relative efficacy.
Within the clinical cure network, there was variation in both
the eligibility criteria for cases among trials, and in the measure-
ment of the outcome. These sources of variation both have the
potential to contribute to heterogeneity in the analyses. Without
adequate precision, it is not possible to assess heterogeneity
within any pairwise comparison between two intervention arms
in the network. Additionally, if it had been possible to analyze
networks for different bacteriologic cure for one or more species,
it would have been interesting to contrast the results with the
results from the clinical cure network, as there was more (but
not absolute) similarity between definition of cases and cure
within each network for the bacterial cure outcomes.
Potential for bias arising from missing outcome data was seen
in many trials for both outcomes, often due to a lack of reporting
the number of study units analyzed. Although the information on
randomization was not reported in a large number of trials, those
which did report randomization often included the method used
to generate the randomization sequence (i.e. few studies included
the word ‘random’ without providing supporting evidence).
Selective reporting of results was also challenging to assess, as
without assessment of a trial protocol developed a priori, it is
not possible to determine the potential for a multiplicity of out-
come definitions or analyses. However, it is likely that the vast
majority of, if not all, clinical trials in this area do have protocols
developed prior to study conduct, in order to obtain ethical
approval for use of animals. Including a time-stamped PDF doc-
umenting the original study protocol as supplementary material
would aid the reader or reviewer in the interpretation of the work.
A lack of reporting key design features is consistent with recent
evaluations of animal health research (Totton et al., 2018; Winder
et al., 2019), and a lack of reporting has been associated with
exaggerated treatment effects (Wellman and O’Connor, 2007;
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reporting preclude assessment for potential bias, but failure to
report characteristics of data may also prevent inclusion in the
meta-analysis. Indeed, in 7/54 (13%) of eligible trials, data were
not able to be extracted for either bacteriologic or clinical cure.
Reporting guidelines, such as the Reporting guidElines For rando-
mized control trials in livEstoCk and food safTey (REFLECT)
statement, have been designed in order to improve the quality
of reporting of trials (O’Connor et al., 2010; Sargeant et al.,
2010). Adherence to reporting guidelines will improve the utility
of future research.
Limitations of the review
Only English-language studies were included, and therefore this
review may not reflect the entirety of literature assessing the effi-
cacy of lactating cow therapy on the bacteriologic and clinical cure
of clinical mastitis. Additional studies would have increased the
precision of our estimates. Decisions on what constituted unique
treatments would influence potential heterogeneity within com-
parisons, but we attempted to be transparent on how decisions
were made to group data. Challenge trials were not considered
Fig. 8. (a–d) The distribution of the probability of clinical cure in the 5000 simulations in the network meta-analysis examining the relative efficacy of antimicrobial
treatments given for clinical mastitis, shown for treatments available as a currently labeled intramammary product in North America.
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eligible for this review. While they provide proof of concept, we
did not feel they could be combined with natural disease exposure
studies to determine relative efficacy under field conditions
(Sargeant et al., 2014a, 2014b), and may be more likely to show
beneficial effects (Wisener et al., 2014).
Conclusions
From the network of evidence, there were no definitive conclu-
sions regarding the relative efficacy of intramammary lactating
cow therapy for clinical mastitis. This was primarily driven by a
lack of precision of estimates for clinical cure and disparate
networks for bacteriologic cures, meaning that information
from several treatment comparisons could not contribute to a lar-
ger body of evidence of relative efficacy. Results from the clinical
cure outcome network could be further confounded by pathogen
causing the clinical mastitis, given the small number of trials.
Consideration of the geometry of these networks can serve to
inform future research, as both replication of important interven-
tion arms and consideration of connection to existing networks
would improve the future ability to determine relative efficacy.
This would provide value beyond the comparisons within a
given study, increasing the utility of both current and previous
work. Challenges in the evaluation of bias in primary research
stemmed from a lack of reporting. Consideration of reporting
guidelines would also improve the utility of future research.
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